Hengrui Pharmaceuticals: Plans to submit a new drug application for HRS9531 injection for long-term weight management in the near future.

On July 15th, Hengrui Medicine and American company Kailera Therapeutics jointly announced that the Phase III clinical trial of GLP-1/GIP dual receptor agonist HRS9531 injection for the treatment of obese or overweight subjects in China has achieved positive top-line results. Compared with the placebo, all dosage groups of HRS9531 have shown favorable efficacy in both primary and all key secondary endpoints. Hengrui Medicine plans to submit a new drug application for HRS9531 injection for long-term weight management in China in the near future, while Kailera is advancing global clinical development of HRS9531.